AlphaCentric Advisors’s Novavax NVAX Stock Holding History

AlphaCentric Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150,000	Closed	-$1.04M	–	263
2023 Q1	$1.04M	Buy	150,000 +45,000	+43%	+$414K	0.72%	47
2022 Q4	$1.08M	Buy	+105,000	New	+$1.85M	1.07%	29

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AlphaCentric Advisors's NVAX Position: Q2 2023 in Review

AlphaCentric Advisors sold out of Novavax (NVAX) in Q2 2023, closing a stake of 150,000 shares — an estimated $1.04M sold.

AlphaCentric Advisors first reported a position in NVAX in Q4 2022 and held it in 2 quarters. The position peaked at $1.08M in Q4 2022. 215 funds tracked by Wall St. Rank hold NVAX as of Q2 2023.

AlphaCentric Advisors reported no remaining Novavax position as of Q2 2023 after selling out during the quarter.
AlphaCentric Advisors sold 150,000 Novavax shares in Q2 2023, an estimated $1.04M.
AlphaCentric Advisors first reported a position in Novavax in Q4 2022 and held it in 2 quarters.
AlphaCentric Advisors's Novavax position peaked at $1.08M in Q4 2022.
215 funds tracked by Wall St. Rank held Novavax as of Q2 2023.

Based on AlphaCentric Advisors's 13F filing for Q2 2023, filed 8 Aug 2023.